• 1\. Gender unlimited，18\< Age;

• 2\. Patients diagnosed with B-cell acute lymphoblastic leukemia through histological or immunophenotyping tests; The clear diagnosis of B-cell non Hodgkin's lymphoma by cellular or histopathological examination mainly includes diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma

• 3\. Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions):

‣ CR not achieved after standardized chemotherapy;

⁃ CR achieved following the first induction, but CR duration is less than 12 months;

⁃ Ineffectively after first or multiple remedial treatments;

⁃ 2 or more relapses;

• 4\. The number of primordial cells (lymphoblast and prolymphocyte) in bone marrow is \>5% (by morphology), and/or \>1% (by flow cytometry);

• 5\. Philadelphia-chromosome-negative (Ph-) patients; or Philadelphia-chromosome-positive (Ph+) patients who cannot tolerate TKI treatments or do not respond to 2 TKI treatments;

• 6\. Relapsed or refractory B-NHL (meeting one of the following conditions):

‣ No response or relapse after second-line or above chemotherapy regimens;

⁃ Primary drug resistance;

⁃ Relapse after auto-HSCT;

• 7\. At least one assessable tumor lesion per Lugano 2014 criteria;

• 8\. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L;

• 9\. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;

• 10\. No active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%;

• 11\. Estimated survival time ≥ 3 months;

• 12\. ECOG performance status 0 to 2;

• 13\. Patients or their legal guardians volunteer to participate in the study and sign the informed consent.